---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-034698"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2026-08-27T20:15:47+00:00"
generated_at: "2026-08-27T20:17:22.800990+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences acquired by argenx for $77.00/share, ~$2.2B; delisting planned

## Summary
- Tender offer accepted 19,894,879 shares (~87.13% of outstanding) at $77.00/share cash.
- Merger completed Aug 27, 2026; Forte is now a wholly owned subsidiary of argenx BV.
- Total consideration ~$2.2B funded from argenx cash; covers options, RSUs, warrants.
- All prior directors/officers replaced; new board includes Arjen Lemmen, Karl Gubitz, Malini Moorthy.
- Company requested Nasdaq delisting and will file Form 15 to suspend SEC reporting.

## SEC filing metadata
- accession: 0001140361-26-034698
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2026-08-27T20:15:47+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000114036126034698/0001140361-26-034698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000114036126034698/ef20081182_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-034698
- JSON: https://secwatch.observer/filing/0001140361-26-034698.json
- Plain text: https://secwatch.observer/filing/0001140361-26-034698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.